Ep4 antagonist compound as well as salt, polymorph and use thereof
AssigneeWuhan Humanwell Innovative Drug Research and Development Center Limited Company
InventorsXuejun ZHANG, Yang YUE, Yang ZANG, Sijun LEI, Qingfeng XIA, Yuan LI, Zhe LIU, Jun YANG, Li'e LI
Life of this patent
Estimating the term…
Abstract
An EP4 antagonist represented by formula I, which specifically comprises a crystal form thereof, a pharmaceutically acceptable salt or crystal form thereof, a preparation method therefor, a composition containing same, and a medical use of a related compound. The structure of formula I is shown below:
Claims19
A crystal form of a compound of formula I, wherein the compound of formula I has a structure as follows:
A pharmaceutically acceptable salt of a compound of formula I, or a crystal form thereof, wherein the pharmaceutically acceptable salt is selected from an alkali metal salt (e.g., a sodium salt or potassium salt), an alkaline earth metal salt (e.g., a calcium salt or magnesium salt), or an ammonium salt of the compound of formula I, or may be selected from a salt formed with an organic base that provides a physiologically acceptable cation, such as a salt formed with the following bases:
- sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, zinc hydroxide, betaine, monoethanolamine, caffeine, urea, nicotinamide, isonicotine, dimethylglucamine, ethylglucamine, glucosamine, meglumine, lysine, arginine, choline, aqueous ammonia, dicyclohexylamine, 1,6-hexanediamine, ethanolamine, diethanolamine, sarcosine, serinol, tris (hydroxymethyl) aminomethane, aminopropanediol, tromethamine, diethylamine, and imidazole;
- preferably, the pharmaceutically acceptable salt of the compound of formula I is a tromethamine salt, a diethylamine salt, and a lysine salt of the compound of formula I;
- the compound of formula I has a structure as follows:
-14. (canceled)
Dependencies are inferred from the claim text.